if you’re going to throw accusations around then please get your facts right. It’s a 6 week (not 6 month) stabilisation. (See American Congress abstract link I previously posted).
> some of the 133 will have failed screening process and be rejected patients , they don’t count for trial
> treverea sparsentan trial in Fgs screened 724 patients to end up with 371 meaning almost 50% screen fail (see published paper available on line)
> only the randomised number matters for trial timelines as with any trial. There must be an update on numbers at some stage , biotechs always update market on this don’t they? so we’ll all know soon enough what progress has been since July 2023 ANN said 72nd patient randomised. By your logic that number should be well over 100 randomise into the trial by now , let’s see.
- Forums
- ASX - By Stock
- DXB
- Ann: ACTION3 IND Approved in China
Ann: ACTION3 IND Approved in China, page-98
-
- There are more pages in this discussion • 134 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
|
|||||
Last
45.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $250.5M |
Open | High | Low | Value | Volume |
46.5¢ | 47.5¢ | 45.5¢ | $934.4K | 2.015M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 548864 | 45.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
46.0¢ | 35747 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 453731 | 0.450 |
1 | 68489 | 0.445 |
2 | 20570 | 0.440 |
2 | 27023 | 0.435 |
4 | 50806 | 0.430 |
Price($) | Vol. | No. |
---|---|---|
0.460 | 17769 | 1 |
0.465 | 71700 | 2 |
0.470 | 55000 | 1 |
0.480 | 91130 | 3 |
0.485 | 85000 | 2 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |